Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1186/1756-9966-32-92.pdf
Reference50 articles.
1. Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, Rizzo G, Bonetti LR, Genovese G, Stigliano E, Cittadini A, Sgambato A: Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012, 31: 71-10.1186/1756-9966-31-71.
2. Edwards MS, Chadda SD, Zhao Z, Barber BL, Sykes DP: A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2012, 14 (suppl 2): e31-e47.
3. Jass JR: Colorectal cancer: a multipathway disease. Crit Rev Oncog. 2006, 12 (suppl 3–4): 273-287.
4. Ciardiello F, Tortora G: Drug therapy: EGFR antagonists in cancer treatment. NEJM. 2008, 358 (suppl 11): 1160-1174.
5. Reynolds NA, Wagstaff AJ: Cetuximab. In the treatment of metastatic colorectal cancer. Drugs. 2004, 64 (suppl 1): 109-118.
Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation;Frontiers in Oncology;2024-01-25
2. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer;BMC Cancer;2024-01-02
3. Progress of research on molecular targeted therapies for colorectal cancer;Frontiers in Pharmacology;2023-08-08
4. Mathematical Modelling of Cancer Growth and Drug Treatments: Taking Into Account Cell Population Heterogeneity and Plasticity;2023 European Control Conference (ECC);2023-06-13
5. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer;Frontiers in Oncology;2023-02-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3